Renal dysfunction as a marker of increased vascular risk

British Journal of Diabetes and Vascular Disease

Volumn 4, Issue 3, 2004, Pages 152-155

  Andrews, Peter ^a  

^a ST HELIER HOSPITAL   (United Kingdom)

Author keywords

Atherosclerosis; Renal impairment; Serum creantine; Vascular disease

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ANALYTICAL ERROR; CARDIOVASCULAR RISK; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DISEASE MARKER; HUMAN; HYPERTENSION; KIDNEY DYSFUNCTION; MORBIDITY; MORTALITY; PREDICTION; PREVENTIVE MEDICINE; PRIMARY MEDICAL CARE; REVIEW; RISK ASSESSMENT; RISK REDUCTION; SECONDARY PREVENTION; VASCULAR DISEASE;

EID: 3242784273     PISSN: 14746514     EISSN: None     Source Type: Journal    
DOI: 10.1177/14746514040040030301     Document Type: Review

References (17)

1. Parfrey JS, Foley RN. The clinical epidemiology of cardiac disease in chronic renal failure. J Am Soc Nephrol 1999;10:1606-15.
2. Goodman WG, Goldin J, Kuizon BD et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 2000;342:1478.
3. Franklin SS, Khan SA, Wong ND et al. Is pulse pressure useful in predicting risk for coronary heart disease? The Framingham Heart Study. Circulation 1999;100:354-60.
4. Levin A, Thompson CR, Ethier J et al. Left ventricular mass index increase in early renal disease: impact of decline in haemoglobin. Am J Kid Dis 1999;34:125-34.
5. Culleton BF, Larson MG, Wilson PW et al. Cardiovascular disease and mortality in a community-based cohort with mild renal insufficiency Kidney Int 1999;56:2214-19.
6. Wannamethee SG, Shaper AG, Perry IJ. Serum creatinine concentration and risk of cardiovascular disease: a possible marker of increased risk of stroke. Stroke 1997;28:557-63.
7. Henry DMA, Kostense PJ, Bos G, Stehouvver CDA. Mild renal insufficiency is associated with increased cardiovascular mortality: the Hoorn Study. Kidney Int 2002;62:1402-07.
8. ARIC study. J Am Soc Nephrol 2001;12:225A.
9. Mann JF, Gerstein HC, Pogue J, Bosch J, Yusuf S. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Ann Intern Med 2001;134:629-36.
10. Haffner SM, Lehto S, Ronnemaa T, Pylorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in non-diabetic subjects with and without prior myocardial infarction. N Engl J Med 1998;339:229-34.
11. Ruilope LM, Salvetti A, Jamerson K et al. Renal function and intensive lowering of blood pressure in hypertensive participants of the hypertension optimal treatment (HOT) study. J Am Soc Nephrol 2001;12:218-25.
12. Shulman NB, Ford CE, Hall WD et al. Prognostic value of serum creatinine and effect of treatment of hypertension on renal function. Results form the hypertension detection and follow-up programme. The Hypertension Detection and Follow-up Program Cooperative Group. Hypertension 1989;13(suppl 5):180-93.
13. Flack JM, Neaton JD, Daniels B et al. Ethnicity and renal disease: Lessons from the MRFIT trial and the treatment of mild hypertension study. Am J Kidn Dis 1993;21(suppl 1):31-40.
14. Dinneen SF, Gerstein HC. The association of microalbuminuria and mortality in non-insulin-dependent diabetes mellitus. A systematic overview of the literature. Arch Intern Med 1997;157:1413-18.
15. Viberti G, Chaturvedi N. Angiotensin converting enzyme inhibitors in diabetic patients with microalbuminura or normoalbuminuria. Kidney Int 1997;63:S32-S35.
16. SIGN. Management of Diabetes. 55, 2001. Edinburgh, Scottish Intercollegiate Guideline Network. www.sign.ac.uk
17. The HOPE investigators. Effects of an ACE inhibitor, ramipril, on cardiovascular events in high risk patients. N Engl J Med 2000;342:145-53.